fashion -WSS

fashion

author：leisure time 2025-10-01 22:16:12 - browse：2577

What makes a blockbuster? Can biotech learn from Aduhelm? And how do you replace a singular regulator?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We explain the debate over Vertex Pharmaceuticals’ novel pain drug, whose success in clinical trials comes with a sizable caveat. We also talk about the latest news in the life sciences, including an epitaph for Aduhelm and the retirement of an FDA icon.

For more on what we cover, here’s the news on Vertex; here’s more on Aduhelm; here’s the exit interview with Janet Woodcock; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Medicaid, Medicare dual

WSS

Menendez indictment could see pharma lose a key ally

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Shingles, which affected Dianne Feinstein, is on the rise

How one patient went off dialysis — and others can too

Did you have Obamacare on your GOP debate bingo card?

Ionis has late

leisure time

fashion

leisure time

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

State Dept. review finds Biden bears some blame for Afghanistan failures

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Alkermes shareholders re

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

BioMarin wins approval for gene therapy to treat hemophilia A

Inequities make cancer less preventable for women: report

Peter Hotez and the public health issue of online harassment

Health tech startups drop sharply from 2021 highs

focus

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Ionis has late

Tocagen's brain cancer gene therapy trial continues. Investors worry

Tocagen's brain cancer gene therapy trial continues. Investors worry

Intercept Pharmaceuticals sells itself for less than $1 billion

FDA advisers vote against ALS treatment from BrainStorm

focus

leisure time

knowledge

Wikipedia